Diagnosis, Pathological Findings, and Clinical Management of Gangliocytic Paraganglioma: A Systematic Review
- PMID: 30101131
- PMCID: PMC6072869
- DOI: 10.3389/fonc.2018.00291
Diagnosis, Pathological Findings, and Clinical Management of Gangliocytic Paraganglioma: A Systematic Review
Abstract
Background: Although gangliocytic paraganglioma (GP) is considered a rare benign neuroendocrine tumor, cases of mortality have been reported. Occasionally, GP is misdiagnosed as neuroendocrine tumor G1, which is associated with a poorer prognosis than GP. To avoid such misdiagnoses, it is important to understand the clinicopathological characteristics of GP. Thus, herein, we discuss the current literature on the clinicopathological characteristics of GP. Methods: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. PubMed and Japana Centra Revuo Medicina searches were used to identify papers describing GP. Inclusion criteria included confirmation of epithelioid, spindle-shaped, and ganglion-like cells in the main article and/or figures and whether the paper was cited in other studies of GP. Data were collected on age, sex, site of the primary lesion, tumor size, treatment, prognosis, lymph node metastasis (LNM), depth of tumor invasion, rate of preoperative diagnosis, and clinical symptoms. Results: In total, 162 papers containing 263 cases of GP met the criteria. The mean age at diagnosis was 53.5 years. The male-to-female ratio was 157:104. The mean tumor size was 25.7 mm. The predominant site of the primary tumor was the duodenum (89.7%). The most common clinical sign of GP was gastrointestinal bleeding (47.9%). Other signs and symptoms of GP included abdominal pain (44.7%), anemia (20.3%), incidental findings (12.9%), nausea (6.9%), weight loss (5.5%), general fatigue (5.1%), jaundice (4.6%), and incidental autopsy findings (5.1%). LNM was observed in 11.4% of patients. Liver metastasis was observed in 1.1% of patients. Depth of tumor invasion (penetrating beyond the submucosal layer or sphincter of Oddi) was by far the most significant risk factor for LNM in patients with GP. This suggests, along with histological heterogeneity, that GP may have hamartomatous characteristics. Furthermore, immunohistochemical expression of progesterone receptor and pancreatic polypeptide were useful in distinguishing between GP and neuroendocrine tumor G1, even in small biopsy specimens. Conclusions: We reveal the clinicopathological characteristics of GP, including risk factors for LNM, differential diagnostic approaches, and improvements in the clinical management of this tumor.In addition, GP may have hamartomatous characteristics.
Keywords: gangliocytic paraganglioma; literature survey; metastasis; neuroendocrine tumor; pancreatic polypeptide; progesterone receptor.
Figures




Similar articles
-
Gangliocytic paraganglioma: An overview and future perspective.World J Clin Oncol. 2019 Sep 24;10(9):300-302. doi: 10.5306/wjco.v10.i9.300. World J Clin Oncol. 2019. PMID: 31572665 Free PMC article.
-
Duodenal Rare Neuroendocrine Tumor: Clinicopathological Characteristics of Patients with Gangliocytic Paraganglioma.Gastroenterol Res Pract. 2016;2016:5257312. doi: 10.1155/2016/5257312. Epub 2016 Dec 21. Gastroenterol Res Pract. 2016. PMID: 28096810 Free PMC article. Review.
-
Pancreatic gangliocytic paraganglioma harboring lymph node metastasis: a case report and literature review.Diagn Pathol. 2017 Aug 2;12(1):57. doi: 10.1186/s13000-017-0648-x. Diagn Pathol. 2017. PMID: 28764742 Free PMC article. Review.
-
Gangliocytic paraganglioma: a multi-institutional retrospective study in Japan.BMC Cancer. 2015 Apr 12;15:269. doi: 10.1186/s12885-015-1308-8. BMC Cancer. 2015. PMID: 25886293 Free PMC article.
-
Duodenal gangliocytic paraganglioma with lymph node metastases: A case report and comparative review of 31 cases.World J Clin Cases. 2017 Jun 16;5(6):222-233. doi: 10.12998/wjcc.v5.i6.222. World J Clin Cases. 2017. PMID: 28685135 Free PMC article.
Cited by
-
Biliary Neuroendocrine Neoplasms: Clinical Profiles, Management, and Analysis of Prognostic Factors.Front Oncol. 2019 Feb 5;9:38. doi: 10.3389/fonc.2019.00038. eCollection 2019. Front Oncol. 2019. PMID: 30805307 Free PMC article.
-
Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.Endocr Pathol. 2021 Mar;32(1):169-191. doi: 10.1007/s12022-021-09662-5. Epub 2021 Jan 18. Endocr Pathol. 2021. PMID: 33459926 Review.
-
Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.Front Endocrinol (Lausanne). 2021 May 6;12:678869. doi: 10.3389/fendo.2021.678869. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34025587 Free PMC article. Review.
-
Gangliocytic Paraganglioma of the Duodenum: A Masquerader.Ochsner J. 2023 Fall;23(3):251-256. doi: 10.31486/toj.23.0010. Ochsner J. 2023. PMID: 37711472 Free PMC article.
-
Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum.Pathologica. 2021 Feb;113(1):12-18. doi: 10.32074/1591-951X-228. Pathologica. 2021. PMID: 33686306 Free PMC article. Review.
References
-
- Amin SM, Albrechtsen NW, Forster J, Damjanov I. Gangliocytic paraganglioma of duodenum metastatic to lymph nodes and liver and extending into the retropancreatic space. Pathologica (2013) 105:90–3. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous